期刊论文详细信息
NEUROPHARMACOLOGY 卷:125
Valproate increases dopamine transporter expression through histone acetylation and enhanced promoter binding of Nurr1
Article
Green, Ashley L.1  Zhan, Le2  Eid, Aseel3  Zarbl, Helmut1  Guo, Grace L.2  Richardson, Jason R.1,3 
[1] Rutgers Robert Wood Johnson Med Sch, Dept Environm & Occupat Med, Environm & Occupat Hlth Sci Inst, Piscataway, NJ USA
[2] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmacol & Toxicol, Piscataway, NJ USA
[3] Northeast Ohio Med Univ, Ctr Neurodegenerat Dis & Aging, Dept Pharmaceut Sci, Rootstown, OH USA
关键词: Dopamine transporter;    Epigenetics;    HDAC;    Valproate;    Histone deacetylase;    Pitx3;    Nurr1;   
DOI  :  10.1016/j.neuropharm.2017.07.020
来源: Elsevier
PDF
【 摘 要 】

The dopamine transporter (DAT) is the key regulator of dopaminergic transmission and is a target of several xenobiotics, including pesticides and pharmacological agents. Previously, we identified a prominent role for histone deacetylases in the regulation of DAT expression. Here, we utilized a rat dopaminergic cell line (N27) to probe the responsiveness of DAT mRNA expression to inhibitors of histone acetylation. Inhibition of histone deacetylases (HDACs) by valproate, butyrate and Trichostatin A led to a 3-10-fold increase in DAT mRNA expression, a 50% increase in protein levels, which were accompanied by increased H3 acetylation levels. To confirm the mechanism of valproate-mediated increase in DAT mRNA, chromatin immunoprecipitation (ChIP) assays were used and demonstrated a significant increase in enrichment of acetylation of histone 3 on lysines 9 and 14 (H3K9/K14ac) in the DAT promoter. Expression of Nurrl and Pitx3, key regulators of DAT expression, were increased following valproate treatment and Nurr1 binding was enriched in the DAT promoter. Together, these results indicate that histone acetylation and subsequent enhancement of transcription factor binding are plausible mechanisms for DAT regulation by valproate and, perhaps, by other xenobiotics. (C) 2017 Elsevier Ltd. All rights reserved.

【 授权许可】

Free   

【 预 览 】
附件列表
Files Size Format View
10_1016_j_neuropharm_2017_07_020.pdf 2842KB PDF download
  文献评价指标  
  下载次数:4次 浏览次数:0次